Physeon GmbH to Attend RESI Investor Conference in Toronto Canada on April 10, 2018
Physeon® GmbH, a leading developer of medical technology products for venous access, today announced that the Company will attend the RESI “Early Stage Investors and Strategic Partners” meeting being held in Toronto, Canada on April 10, 2018. This meeting will match companies with potential investors, CEO’s and scientist-entrepreneurs in this highly respected venue of Toronto, the Medtech capital of Canada.
The Redefining Early Stage Investments (RESI) Conference is an ongoing conference series that provides an international venue for early stage life science companies across Biotech, Medtech, Diagnostics and Healthcare IT. It’s a place to source investors from around the globe, create relationships, and eventually, secure funding.
Patrick Kullmann, Physeon Chief Executive Officer, commented on the market opportunity for Physeon and the Veinplicity® product, “Veinplicity is designed to aid peripheral IV cannulation, the single most common medical intervention performed each day in hospitals.
Although up to 80% of patients need a peripheral IV cannula, a significant proportion of the population have veins that are difficult to access. Successful venous cannulation is challenged by a patient’s anatomy and disease state amongst other factors and failure leads to delayed treatment, increased costs and patient discomfort.”
Kullmann added, “Veinplicity addresses these challenges by significantly increasing the size, rigidity and stability of forearm veins, making them easier to find and easier to cannulate first time. Consisting of a portable electronic stimulation device which passes a gentle current between electrodes placed on the palm and the bicep, Veinplicity is the only technology available which has a physiological effect on veins. The system perfectly fits the “razor-razor blade” medical model for success.”
Veinplicity is CE Marked and is available outside the US, it is not FDA approved and not for sale in the US.
Established in 2015 and located in Schaffhausen, Switzerland, Physeon is a boutique medical device company created to guide the development and commercialization of new innovations in healthcare. We embrace research and science to bring about innovative ideas and medical products that can advance the health and well-being of patients and simplify processes for healthcare professionals. Veinplicity is CE marked and is available on a limited basis in the EU. It is not yet FDA approved and is not yet commercially available in the US. For more information, visit www.physeon.com.